A randomized trial involving 192 patients with gradual-onset, midportion Achilles tendinopathy revealed that high-volume injections, including saline, bupivacaine alone, bupivacaine plus hydrocortisone, or bupivacaine delivered to an ineffective site, did not demonstrate significant benefit compared to sham injections after 12 months. AUS, COVID-19, and VISA-A were key elements of this research.
Key Clinical Findings
Patients averaged approximately 50 on the Victorian Institute of Sport Assessment-Achilles (VISA-A) instrument at baseline. Improvements were similar across all three arms at week 52, with no statistically significant differences observed. At 6 weeks, the bupivacaine-steroid combination provided greater relief than the other arms, approximately 10 points on the VISA-A scale, but this advantage diminished by week 12 and numerically reversed by week 26.
Healthcare Cost Analysis
Healthcare costs were more favorable with the bupivacaine-steroid combination compared to the sham injection, with greater than 90% certainty of cost-effectiveness at thresholds of AUS$50,000 to $100,000. Patients received approximately 10 mL of 0.5% bupivacaine and 40 mL saline, or 25-mg hydrocortisone in the steroid-included arm. Sham injections were delivered at least 10 mm anterior to the junction, producing a numbing effect. Adverse effects were generally mild and infrequent, with aggravated Achilles pain occurring in varying percentages across the arms. Eleven participants did not collect VISA-A scores at week 52, and per-protocol analyses yielded similar results. The study acknowledged limitations including recruitment through social media and adaptations due to the **COVID-19** pandemic.